Januar 08, 2014 – Novartis recently published a comprehensive overview of its Corporate Responsibility strategy and programs.
- Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US
- Biosimilar filgrastim recommended to be approved for use in all requested indications
- Committee’s recommendation based on review of extensive data from analytical, non-clinical, clinical studies and post-marketing pharmacovigilance
Holzkirchen, January 7, 2014 – Sandoz, a Novartis company, announced today that US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of its …
Munich, December 18, 2013 – Sandoz announced today that it has received Danish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). The Danish approval follows the completion of EU decentralized procedures (DCP) for eight EU countries, including Denmark.
- Novel inhaler approved for patients with asthma and COPD
- Approval follows completion of EU decentralized procedure (DCP)
- AirFluSal® Forspiro® strengthens Sandoz respiratory portfolio and …
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia